Parnax Lab Ltd.
Snapshot View

View in App

Prices View details >>

50.48 -0.73 ▼-1.4%

29 March 2023, 04:01:00 PM
Volume: 20,755

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.naxparlab.com
Market Cap 57.98 Cr.
Enterprise Value(EV) 111.86 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 6.12 Trailing Twelve Months Ending 2022-12
Price-Earning Ratio (PE) 8.25 Trailing Twelve Months Ending 2022-12
Industry PE 32.17 Trailing Twelve Months Ending 2022-12
Book Value / Share 52.96 Trailing Twelve Months Ending 2022-12
Price to Book Value 0.95 Calculated using Price: 50.48
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 1.15 Cr. 11,485,616 Shares
FaceValue 10
Company Profile
Parnax Lab, earlier known as Krishnadeep Trade and Investments, incorporated in the year 1982, engages in investing and financial businesses in India. The company is based in Mumbai, India. In 2012 the company has changed its name from Krishna Deep Trade & Investments Ltd. to Parnax Lab Ltd. "

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-1.43%
1 Week
-11.66%
1 Month
-16.91%
3 Month
-31.27%
6 Month
-35.24%
1 Year
-60.76%
2 Year
+150.52%
5 Year
+13.44%
10 Year
+36.43%

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 12.70 18.50 9.50 12.51 3.31 9.69 -8.51 -1.11 20.93
Return on Capital Employed (%) 14.16 16.35 11.47 13.73 10.49 11.59 3.27 5.83 17.34
Return on Assets (%) 3.47 5.12 3.09 4.48 1.22 3.63 -2.89 -0.34 6.36

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 21 25 28 31 33 36 33 33 48 58
Non Curr. Liab. 22 27 23 18 18 23 22 19 24 21
Curr. Liab. 41 31 29 36 37 36 52 54 81 65
Minority Int. 0 0 0 0 0 0 0 0 0 0
Equity & Liab. 83 83 79 86 87 95 107 106 153 143
Non Curr. Assets 37 45 49 55 51 58 62 67 79 79
Curr. Assets 46 38 31 31 36 37 46 39 75 64
Misc. Exp. not W/O 0 0
Total Assets 83 83 79 86 87 95 107 106 153 143

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-12 Rs. Cr. TTM
Net Sales 69 103 71 95 106 109 95 90 163 175
Other Income 1 1 1 1 1 2 1 0 0 1
Total Income 70 104 72 96 107 111 96 90 163 175
Total Expenditure -60 -91 -61 -82 -96 -99 -89 -80 -140 -149
PBIDT 9 13 11 13 11 12 7 10 23 26
Interest -4 -4 -4 -5 -4 -4 -5 -5 -5 -5
Depreciation -2 -3 -3 -4 -4 -4 -4 -5 -6 -7
Taxation -1 -1 -1 -1 -2 -1 -1 0 -4 -7
Exceptional Items 0
PAT 2 4 3 4 1 3 -3 0 8 7
Minority Interest 0 0 0 0 0 0 0
Share Associate
Other Related Items
Consolidated Net Profit 2 4 3 4 1 3 -3 0 8 7
Adjusted EPS 3 5 3 4 1 4 -3 0 8 6

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 6 0 0 3 16 13 9 9 6 9
Cash Fr. Inv. -1 -6 -4 -6 -10 -5 -11 -13 -7 -17
Cash Fr. Finan. -3 6 6 1 -5 -7 1 5 0 12
Net Change 1 0 1 -2 0 1 -1 0 0 4
Cash & Cash Eqvt 1 1 2 0 0 1 0 0 0 4

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 62.59 62.59 62.59 62.59 62.59 67.58 67.58 72.30 72.30
Public 37.41 37.41 37.41 37.41 37.41 32.42 32.42 27.70 27.70
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 14.68 14.68 14.68 14.68 14.68 11.78 11.78 9.41 9.41

Announcements View Details >>

Tue, 14 Feb 2023
Board Meeting Outcome for Board Meeting Of The Company To Consider And Approved The Standalone & Consolidated Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended 31St Dec 2022 Along With The Limited Review Report Thereon.
Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday 14th February 2023 at its Registered Office the Board inter alia has transacted the following business:1. Considered and Approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and nine months ended 31st December 2022 along with the Limited Review Report thereon.The Meeting commenced at 5.00 p.m. and concluded at 5.45 p.m.Kindly take the same on your record & Oblige.
Tue, 14 Feb 2023
Results-Un-Audited Financial Results For The Quarter Ended December 31 2022.
Kindly find enclosed herewith a Copy of the Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and nine months ended December 31 2022 along with the Limited Review Report thereon pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations 2015.The aforesaid information and Financial Results are being made available on the Companys website at www.naxparlab.comKindly take on your record and acknowledge receipt of the same.
Tue, 14 Feb 2023
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015
Pursuant to Regulation 8 (2) of the SEBI (Prohibition of Insider Trading) Regulations 2015 as amended by SEBI (Prohibition of Insider Trading) (Amendment) Regulations 2018 the Board of Directors of the Company has revised the Companys "Code for Fair Disclosure of Unpublished Price Sensitive Information" which is also available on the website of the Company i.e. www.naxparlab.com.

Technical Scans View Details >>

Wed, 29 Mar 2023
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 237,702.12 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. 76,011.65 4,564.50 +0.8%
Divi's Laboratories Ltd. 74,827.63 2,818.70 +0.5%
Cipla Ltd. 71,662.87 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. 62,756.97 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. 52,113.83 1,554.65 +0.7%
Zydus Lifesciences Ltd. 49,628.37 490.30 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 56.44 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 20.86 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-12 31.22 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-12 27.16 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 82.20 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 63.32 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-12 24.08 490.30 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.36 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.37 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-12 5.66 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-12 3.10 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 9.90 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 7.53 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.77 490.30 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 0.04 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 490.30 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 13.10 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 490.30 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 13.10 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 490.30 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 490.30 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 490.30 +1.2%

FAQ's On Parnax Lab Ltd.

What is Parnax Lab share price?
Can I buy Parnax Lab shares now?
What is the Market Cap of Parnax Lab?
What are the key metrics to analyse Parnax Lab?
What is the 52 Week High and Low of Parnax Lab?
What is the trend of Parnax Lab share price?